This week, Informa’s Finance and Accounting for Bioscience takes place in Boston, offering pharma professionals a place to learn, network, and discuss a variety of relvant topics. These include sessions on the 2027 finance outlook; controllership concerns; SEC and FASB presentations; and sessions for pre-commercial and commercial stage biopharma finance groups.
Adam S. Mostafa, chief financial officer and head of business development at Sitryx Therapeutics, serves as chairperson of the event. He was interviewed by BioXconomy while in his prior role at X4 Pharmaceuticals.
Also presenting at the event this week are the following experts:
Gina Tracey, corporate controller at Alnylam Pharmaceuticals, recently spoke to the pharma finance and accounting professionals audience about talent needs in companies at various stages of growth in biotech. This week, she will join a panel on optimizing ERP systems for growth.
Justin Renz, who took on the role of chief financial officer of Zevra Therapeutics earlier this year, will bring his extensive biopharmaceutical financial leadership experience to the CFO Panel to discuss “Redefining Financial Leadership for Organizational Success.”
Mallory Morales, senior vice president of finance, chief accounting officer, and treasurer of Immuneering, will speak to “Preparing for Long-Term Growth: Strategies for Funding Opportunities and Operational Readiness.” Here, BioXconomy interviewed Morales prior to her presenting at this event in 2025.
While you catch up on these past articles, look at our coverage of the event available throughout the month or in the October 27 enewsletter.
Read More: Biopharma CFOs discuss finance strategies
